AGENDA

Agenda – Day One

Wednesday, May 13

7:30   REGISTRATION & WELCOME COFFEE

8:20   CHAIRPERSON’S OPENING REMARKS

Tom Cronin, Senior Vice President
QUADAX

8:30  PANEL DISCUSSION: THE MANY FACES OF MANAGED CARE: HOW PAYER STRUCTURE SHAPES COVERAGE OF NEW DIAGNOSTICS

• How different health plan structures (e.g., regional plans, Blues plans) influence incentives, operating models, and risk tolerance
• What those structural differences mean for evidence expectations, coverage timelines, and policy variability
• Practical implications for diagnostics companies seeking adoption across heterogeneous payer environments

Moderated by Ann Lambrix, LIGHTHOUSE LAB SERVICES
Mark Hiatt, HIATT ADVISORY SERVICES
Dr. Steven Goldberg, HEALTHTRACKRX
Eugean Jiwanmall, INDEPENDENCE BLUE CROSS FAMILY OF COMPANIES

9:20  FIRESIDE CHAT: COVERAGE DECISIONS AT A BLUES PLAN: WHAT REALLY DRIVES THE “YES” OR “NO”

• Evidence, utilization, and clinical value through a Blues plan lens
• Common misconceptions diagnostics companies have about payer decision-making
• Open discussion driven by attendee questions and real coverage scenarios

Moderated By:
Erik Duffy, Vice President of Market Access
NAVERIS
Barb Liwosz, Director, Lab & Precision Medicine
BCBSA

10:00   COFFEE & NETWORKING BREAK

10:20   DRIVING INNOVATION THROUGH PHARMA-DIAGNOSTICS COLLABORATION

• Shared models between Rx companies and diagnostics for biomarker advancement
• Lessons learned from cardiovascular and oncology biomarker development
• Opportunities for earlier integration of diagnostics into drug development pipelines
• Balancing risks and reward in Rx & Dx alliances to unlock sustainable revenue growth

Paige Nardi, Executive Vice President of Market Access, Reimbursement, & Billing
HEPQUANT

11:20  UNLOCKING DATA, HEOR, AND MARKET TRANSPARENCY IN FUTURE REIMBURSEMENT

• Using HEOR and RWE data in payer evidence discussions: Utilization and Outcomes
• HEOR hierarchy: High-impact strategies in study design for payer decision-making audiences
• Performance metrics for coverage scenarios with laboratory data
• Testing reimbursement strategies

Dr. Julie Wiedower, Senior Director of Medical Affairs & Managed Care
GUARDANT HEALTH

12:00   LUNCHEON

1:00   MOLDX MASTERY: DRIVING SUCCESSFUL SUBMISSIONS AND ACCELERATING MARKET ACCESS

• MolDX’s technical assessments process and what is covered
• Policy development and payer adoption (Medicare vs Commercial)
• Strategies for successfully navigating MolDX submissions
• Case study examples of successful vs stalled submissions

Dr. Gabriel Bien-Willner, MD, PhD, FCAP, Chief Medical Director, MolDX & CMO
PALMETTO GBA

1:50   THE IMPACT OF PAMA IMPLEMENTATION AND POTENTIAL REFORMS ON TODAY’S DIAGNOSTIC LANDSCAPE

• Current status of PAMA implementation and enforcement
• Ongoing reform efforts and their implications for labs
• Impacts of other regulatory and administrative changes for labs
• 2026 regulatory shifts and their impact on reimbursement

Christine Bump, Principal
PENN AVENUE LAW & POLICY

2:30   CASE STUDY: TURNING CLINICAL EVIDENCE IN BROADER MARKET ACCESS SUCCESS

• Building payer confidence through robust clinical data and coding strategy that withstands scrutiny
• Engaging payers and advocacy partners to navigate policy barriers and accelerate coverage
• Repeatable steps for optimizing reimbursement across diagnostic portfolios

Shivang Doshi, Senior Director, Value & Access Strategy
CEPHEID

3:15   COFFEE & NETWORKING BREAK

3:40   REDEFINING SCREENING & DIAGNOSTIC BOUNDARIES IN COVERAGE POLICY

• FDA and CMS distinctions shaping definitions of screening versus diagnostics
• Preventative versus diagnostic coding rules driving coverage determinations
• Implications for multi-cancer early detection and minimal residual disease tests
• Navigating the ‘valley of death’ between regulatory approval and CMS reimbursement

Dr. Joseph Imperato, Manager, Clinical Operations
CARELON HEALTHCARE SERVICES

4:30  ADVANCING COVERAGE PATHWAYS FOR NEXT-GENERATION SEQUENCING (NGS)

• Review of the 2025 Medicare update on CLIA-certified and physician-ordered testing
• Expanded documentation, coding, and compliance requirements for NGS claims
• Commercial payer responses and evolving criteria for NGS coverage decisions
• Future reimbursement outlook and long-term implications for NGS adoption

Rebecca Hulinsky, Director of Genome Strategy & Solutions
QUEST DIAGNOSTICS

5:15   CLOSING REMARKS AND END DAY ONE

Executive Director, Market Access, ARTERA

Executive Director, Market Access, ASPIRA WOMEN’S HEALTH

Chief Medical Officer, AVALON HEALTHCARE SOLUTIONS

Client Manager,  BEACONONE HEALTHCARE PARTNERS

Senior Vice President, Market Access, BELAY DIAGNOSTICS

Vice President, Market Access, BILLIONTOONE INC.

Vice President, Market Access, BIO-TECHNE/EXOSOME 

Director, Lab and Precision Medicine, BLUE CROSS BLUE SHIELD

Senior Consultant, BLUE CROSS BLUE SHIELD

Senior Director, Market Access, CAREDX

National Account Manager, Managed Care, CASTLE BIOSCIENCES

Vice President of Reimbursement, CASTLE BIOSCIENCES

Senior Global Director, ELI LILLY

Revenue Cycle Billing Manager, EUROFINS – TRANSPLANT GENOMICS

Corporate Account Director, Market Access, EXOSOME DX

Director of Market Access, GENEDX INC

Chief Executive Officer, GENOMIND

Chief Commercial Officer, GLX ANALYTICS

Senior Director, Reimbursement & Policy, GRAIL

Vice President, Managed Care, GUARDANT HEALTH

Vice President, Market Access, Reimbursement & Billing, HEPQUANT

Senior Director of Market Access, HOLOGIC

Precision Medicine Value & Access, J&J INNOVATIVE MEDICINE

Medical Affairs Director, MERCK